A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Therapeutic Activity of ORE1001 in Subjects With Ulcerative Colitis.
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs GL 1001 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2011 Planned end date changed from Feb 2011 to Jun 2011 as reported by ClinicalTrials.gov.
- 13 Aug 2010 Planned end date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.